The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the potential ...

Harnessing surface engineering strategies to functionalize nucleic acid-lipid nanoparticles (LNPs) for improved performance has been a hot research topic since the approval of the first siRNA drug, ...

Anti-nucleolin DNA aptamer, iSN04, inhibits angiogenesis. Mouse aortic rings embedded in collagen gel were cultured with or without 30 µM iSN04 for 6 days. Neovascular sprouting, a model of ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

Jacob Petersen, DMSc, Novo Nordisk senior vice president, head of global nucleic acid therapies [GEN/Alex Philippidis] LEXINGTON, MA—For Jacob Petersen, DMSc, Novo Nordisk’s quest to treat diabetes ...